BTK and myeloid sarcoma: By eliminating EBV from the equation (i.c. by HSCT, anti-B-cell or anti-EBV T-cell therapy), and by inhibiting specific receptor-driven signaling (BTK, MAPK-ERK, JAK/STAT) or inducing the natural silencers of these signaling pathways (DUSP6), the multi-component inflammatory cascade underlying MS may be halted (2, 9, 210), overall reducing glia cells and astrocyte activation and inducing myelin damage repair to ultimately restore neural functions.